SEARCH RESULT

Total Matching Records found : 232

In a victory for India and China, WHO evolves mechanism to define counterfeit drugs-Aarti Dhar

-The Hindu The World Health Organisation (WHO) has put in place a mechanism to define counterfeit medical products. The set of definitions of sub-standard, spurious, falsely labelled, falsified and counterfeit products will be globally accepted and help to bring about uniformity in identifying such drugs, without interrupting worldwide supplies. The decision to establish a member state mechanism was taken at the World Health Assembly, the WHO's policymaking body, at a meeting held recently. The...

More »

ACTA will make life saving drugs costlier for the poor-Rachit Ranjan

Joseph Munyi, a Kenyan citizen, has been living with HIV for 8 years and, much like other HIV patients, is unemployed. He has been receiving his medication free of charge on account of government programmes and outreach programmes of Medicine Sans Frontieres. His medication comes in the form of generic drugs. However, this situation may not last long as economic interests of few may end up impeding many a public spirited...

More »

Protests in US over high pricing of Novartis' anti-cancer drug Glivec-Divya Rajagopal

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...

More »

The government needs to think out of the box to help pharma grow while keeping medicines affordable-Ramesh Adige

Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close